Prothena

DB:0PT

Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.

0PT

$427M

Market Cap

Add to portfolio

Last updated 2019/04/19 21:41

Company description

Find similar companies

Add to Portfolio Compare Print

Prothena has significant price volatility in the past 3 months.

0PT Share Price and Events

7 Day Returns

-3.5%

DB:0PT

-1.4%

DE Biotechs

2.4%

DE Market

1 Year Returns

-65.9%

DB:0PT

-10.6%

DE Biotechs

-6.2%

DE Market

0PT Shareholder Return

	7 Day	30 Day	90 Day	1 Year	3 Year	5 Year
Prothena (0PT)	-3.5%	-21.7%	-8.2%	-65.9%	-76.8%	-66.8%
DE Biotechs	-1.4%	2.6%	-7.7%	-10.6%	54.2%	8%
DE Market	2.4%	3%	7.4%	-6.2%	9.6%	14.1%

1 Year Return vs Industry and Market

0PT underperformed the Biotechs industry which returned -10.6% over the past year.
0PT underperformed the Market in Germany which returned -6.2% over the past year.

Price Volatility

0PT

Industry

5yr Volatility vs Market

Related Companies

Sorry, no analysis for Prothena's competitors could be found in our database.

0PT Value

Is Prothena undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS

It is not possible to calculate the future cash flow value for Prothena. This is due to cash flow or dividend data being unavailable. The share price is €9.55.

PRICE RELATIVE TO MARKET

We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Prothena's earnings, growth and assets is considered below, and whether this is a fair price.

Price based on past earnings

Are Prothena's earnings available for a low price, and how does this compare to other companies in the same industry?

Raw Data

DB:0PT PE (Price to Earnings) Ratio Data Sources
Data Point	Source	Value
Earnings Per Share *	Company Filings (2018-12-31) in USD	$-3.93
NasdaqGS:PRTA Share Price **	NasdaqGS (2019-04-18) in USD	$10.7
Europe Biotechs Industry PE Ratio	Median Figure of 30 Publicly-Listed Biotechs Companies	22.41x
Germany Market PE Ratio	Median Figure of 422 Publicly-Listed Companies	19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Prothena.

DB:0PT PE (Price to Earnings) Ratio Calculation
	Calculation	Outcome
PE Ratio	= NasdaqGS:PRTA Share Price ÷ EPS (both in USD) = 10.7 ÷ -3.93	-2.72x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

Prothena is loss making, we can't compare its value to the Europe Biotechs industry average.
Prothena is loss making, we can't compare the value of its earnings to the Germany market.

Price based on expected Growth

Does Prothena's expected growth come at a high price?

Raw Data

DB:0PT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point	Source	Value
PE Ratio	See PE Ratio Section	-2.72x
Net Income Annual Growth Rate	See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts	22.9%per year
Europe Biotechs Industry PEG Ratio	Median Figure of 22 Publicly-Listed Biotechs Companies	1.3x
Germany Market PEG Ratio	Median Figure of 270 Publicly-Listed Companies	1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

Unable to calculate PEG ratio for Prothena, we can't assess if its growth is good value.

Price based on value of assets

What value do investors place on Prothena's assets?

Raw Data

DB:0PT PB (Price to Book) Ratio Data Sources
Data Point	Source	Value
Book Value per Share	Company Filings (2018-12-31) in USD	$8.10
NasdaqGS:PRTA Share Price *	NasdaqGS (2019-04-18) in USD	$10.7
Germany Biotechs Industry PB Ratio	Median Figure of 15 Publicly-Listed Biotechs Companies	3.71x
Germany Market PB Ratio	Median Figure of 570 Publicly-Listed Companies	1.85x

DB:0PT PB (Price to Book) Ratio Calculation
	Calculation	Outcome
PB Ratio	= NasdaqGS:PRTA Share Price ÷ Book Value per Share (both in USD) = 10.7 ÷ 8.10	1.32x

* Primary Listing of Prothena.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

Prothena is good value based on assets compared to the DE Biotechs industry average.

Value checks

We assess Prothena's value by looking at:

Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)

Full details on the Value part of the Simply Wall St company analysis model.

0PT Future Performance

How is Prothena expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!

22.9%

Expected annual growth in earnings.

Earnings growth vs Low Risk Savings

Is Prothena expected to grow at an attractive rate?

Unable to compare Prothena's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.

Growth vs Market Checks

Unable to compare Prothena's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
Prothena's revenue growth is expected to exceed the Germany market average.

Annual Growth Rates Comparison

Raw Data

DB:0PT Future Growth Rates Data Sources
Data Point	Source	Value (per year)
DB:0PT Future Earnings Growth Rate	Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts	22.9%
DB:0PT Future Revenue Growth Rate	Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts	41.9%
Germany Biotechs Industry Earnings Growth Rate	Market Cap Weighted Average	47.5%
Germany Biotechs Industry Revenue Growth Rate	Market Cap Weighted Average	26%
Germany Market Earnings Growth Rate	Market Cap Weighted Average	11.5%
Germany Market Revenue Growth Rate	Market Cap Weighted Average	4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations

Raw Data

DB:0PT Analysts Growth Expectations Data Sources
Data Point	Source	Value
Past Financials	Company Filings (3 months ago)	See Below
Future Estimates	Average of up to 5 Analyst Estimates (S&P Global)	See Below

All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.

DB:0PT Future Estimates Data
Date (Data in USD Millions)	Revenue	Cash Flow	Net Income *	Avg. No. Analysts
2023-12-31	79		-24	1
2022-12-31	11		-85	1
2021-12-31	14	-73	-79	3
2020-12-31	58	-36	-77	5
2019-12-31	1	-60	-96	5

DB:0PT Past Financials Data
Date (Data in USD Millions)	Revenue	Cash Flow	Net Income *
2018-12-31	1	-28	-156
2018-09-30	1	-47	-181
2018-06-30	1	-31	-209
2018-03-31	27	-125	-167
2017-12-31	28	-131	-153
2017-09-30	27	-125	-154
2017-06-30	28	-138	-145
2017-03-31	1	-129	-168
2016-12-31	1	-116	-160
2016-09-30	1	-102	-135
2016-06-30	1	-89	-115
2016-03-31	1	-73	-93

*GAAP earnings excluding extraordinary items.

High Growth Checks

Prothena is not considered high growth as it is expected to be loss making for the next 1-3 years.
Prothena's revenue is expected to grow significantly at over 20% yearly.

Past and Future Earnings per Share

The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.

Raw Data

DB:0PT Past and Future Earnings per Share
Data Point	Source	Value
Past Financials	Company Filings (3 months ago)	See Below
Future Estimates	Average of up to 5 Analyst Estimates (S&P Global)	See Below

All data from Prothena Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0PT Future Estimates Data
Date (Data in USD Millions)	EPS *	EPS High Estimate	EPS Low Estimate	Avg. No. Analysts
2023-12-31	-0.48	-0.29	-0.66	2.00
2022-12-31	-1.77	-1.69	-1.85	2.00
2021-12-31	-1.80	-0.94	-2.31	3.00
2020-12-31	-1.98	-1.08	-2.90	7.00
2019-12-31	-2.45	-2.09	-3.00	7.00

DB:0PT Past Financials Data
Date (Data in USD Millions)	EPS *
2018-12-31	-3.93
2018-09-30	-4.61
2018-06-30	-5.38
2018-03-31	-4.34
2017-12-31	-4.07
2017-09-30	-4.21
2017-06-30	-4.07
2017-03-31	-4.83
2016-12-31	-4.66
2016-09-30	-4.03
2016-06-30	-3.50
2016-03-31	-2.91

*GAAP earnings excluding extraordinary items.

Performance in 3 years

In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.

Unable to establish if Prothena will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Future performance checks

We assess Prothena's future performance by looking at:

Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
Is the annual earnings growth rate expected to be above 20%? (1 check)
Is the annual revenue growth rate expected to be above 20%? (1 check)
Is the Return on Equity in 3 years expected to be over 20%? (1 check)

Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Prothena has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

0PT Past Performance

How has Prothena performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.

Past earnings growth

Below we compare Prothena's growth in the last year to its industry (Biotechs).

Past Earnings growth analysis

We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.

Prothena does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Prothena's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Prothena's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.

Earnings and Revenue History

Prothena's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.

Raw Data

All data from Prothena Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0PT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions)	Revenue	Net Income *	G+A Expenses
2018-12-31	0.96	-155.65	42.48
2018-09-30	0.99	-180.94	48.50
2018-06-30	0.95	-208.78	51.70
2018-03-31	27.49	-166.60	51.62
2017-12-31	27.52	-153.24	48.23
2017-09-30	27.46	-154.38	35.09
2017-06-30	27.53	-145.23	38.78
2017-03-31	1.05	-167.97	36.01
2016-12-31	1.06	-160.11	32.36
2016-09-30	1.19	-135.36	38.08
2016-06-30	1.33	-115.10	27.85
2016-03-31	1.28	-92.93	25.24
2015-12-31	1.61	-80.61	23.11
2015-09-30	3.31	-69.57	21.49
2015-06-30	4.37	-59.77	19.81
2015-03-31	19.21	-40.20	19.23
2014-12-31	50.85	-7.15	19.05
2014-09-30	49.01	-5.09	19.31
2014-06-30	47.69	-1.60	18.47
2014-03-31	32.74	-14.19	16.74
2013-12-31	0.68	-41.00	15.05
2013-09-30	1.08	-42.16	12.74
2013-06-30	1.86	-41.14	11.44
2013-03-31	2.43	-39.55	10.65
2012-12-31	2.66	-41.41	9.93
2012-09-30	2.19	-38.76	8.35
2012-06-30	1.45	-37.29	7.66

*GAAP earnings excluding extraordinary items.

Performance last year

We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.

It is difficult to establish if Prothena has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
It is difficult to establish if Prothena has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
It is difficult to establish if Prothena improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.

Past performance checks

We assess Prothena's performance over the past 5 years by checking for:

Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)

The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Prothena has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

0PT Health

How is Prothena's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Prothena's finances.

The net worth of a company is the difference between its assets and liabilities.

Net Worth

Prothena is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Prothena's cash and other short term assets cover its long term commitments.

Balance sheet

This treemap shows a more detailed breakdown of Prothena's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.

Assets

Liabilities and shares

The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.

Low level of unsold assets.
Debt is covered by short term assets, assets are 8.4x debt.

Historical Debt

Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.

Raw Data

All data from Prothena Company Filings, last reported 3 months ago.

DB:0PT Past Debt and Equity Data
Date (Data in USD Millions)	Total Equity	Total Debt	Cash & Short Term Investments
2018-12-31	323.00	51.55	427.66
2018-09-30	339.65	51.91	451.51
2018-06-30	356.01	52.17	486.21
2018-03-31	409.51	52.20	429.04
2017-12-31	407.19	52.25	417.62
2017-09-30	446.25	52.27	456.06
2017-06-30	486.98	52.15	471.73
2017-03-31	496.25	51.74	506.55
2016-12-31	365.40	51.32	386.92
2016-09-30	401.10	39.36	408.57
2016-06-30	430.87	35.93	442.95
2016-03-31	465.78	0.00	474.25
2015-12-31	360.67	0.00	370.59
2015-09-30	377.95	0.00	387.80
2015-06-30	395.22	0.00	402.39
2015-03-31	277.43	0.00	279.86
2014-12-31	289.89	0.00	293.58
2014-09-30	301.56	0.00	306.15
2014-06-30	298.42	0.00	303.85
2014-03-31	193.01	0.00	195.05
2013-12-31	173.27	0.00	176.68
2013-09-30	98.78	0.00	101.86
2013-06-30	107.23	0.00	112.51
2013-03-31	117.79	0.00	119.56
2012-12-31	126.48	0.00	124.86
2012-09-30	-3.10	0.00
2012-06-30	-2.60	0.00

Prothena's level of debt (16%) compared to net worth is satisfactory (less than 40%).
The level of debt compared to net worth has increased over the past 5 years (0% vs 16% today).

CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Prothena has sufficient cash runway for more than 3 years based on current free cash flow.
Prothena has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -11.6% each year.

Show me more healthy companies in the Biotechs industry

Financial health checks

We assess Prothena's financial health by checking for:

Are short term assets greater than short term liabilities? (1 check)
Are short term assets greater than long term liabilities? (1 check)
Has the debt to equity ratio increased in the past 5 years? (1 check)
Is the debt to equity ratio over 40%? (1 check)
Is the debt covered by operating cash flow? (1 check)
Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)

For companies that are loss making and have been so on average in the past we replace the last 2 checks with:

Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)

Full details on the Health part of the Simply Wall St company analysis model.

0PT Dividends

What is Prothena's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.

Annual Dividend Income

Current annual income from Prothena dividends. Estimated to be 0% next year.

If you bought €2,000 of Prothena shares you are expected to receive €0 in your first year as a dividend.

Dividend Amount

Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?

Unable to evaluate Prothena's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Prothena's dividend against the top 25% market benchmark as the company has not reported any payouts.

Annualized Historical and Future Dividends

It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.

Raw Data

DB:0PT Annualized Past and Future Dividends
Data Point	Source	Value
Past Annualized Dividend Yield	S&P Global Market Data	See Below
Past Dividends per Share	Company Filings/ Annualized Dividend Payments	See Below
Future Dividends per Share Estimates	Average of up to 5 Analyst Estimates (S&P Global)	See Below
Europe Biotechs Industry Average Dividend Yield	Market Cap Weighted Average of 9 Stocks	0.9%
Germany Market Average Dividend Yield	Market Cap Weighted Average of 325 Stocks	3%
Germany Minimum Threshold Dividend Yield	10th Percentile	0.8%
Germany Bottom 25% Dividend Yield	25th Percentile	1.4%
Germany Top 25% Dividend Yield	75th Percentile	3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0PT Future Dividends Estimate Data
Date (Data in $)	Dividend per Share (annual)	Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31	0.00	1.00
2019-12-31	0.00	1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

Unable to perform a dividend volatility check as Prothena has not reported any payouts.
Unable to verify if Prothena's dividend has been increasing as the company has not reported any payouts.

Current Payout to shareholders

What portion of Prothena's earnings are paid to the shareholders as a dividend.

Unable to calculate sustainability of dividends as Prothena has not reported any payouts.

Future Payout to shareholders

No need to calculate the sustainability of Prothena's dividends in 3 years as they are not expected to pay a notable one for Germany.

Income/ dividend checks

We assess Prothena's dividend by checking for:

Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
Is current dividend yield above the bottom 25% of dividend payers? (1 check)
Is current dividend yield above the top 25% of dividend payers? (1 check)
Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
If they have paid a dividend for 10 years has it increased in this time? (1 check)
How sustainable is the dividend, can Prothena afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)

Full details on the Dividends part of the Simply Wall St company analysis model.

0PT Management

What is the CEO of Prothena's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.

CEO

Gene Kinney

COMPENSATION	$11,396,769
AGE	49
TENURE AS CEO	2.6 years

CEO Bio

Mr. Gene G. Kinney, Ph.D., has been the Chief Executive Officer and President of Prothena Corporation plc since September 26, 2016 and October 3, 2016 respectively and served as its Chief Operating Officer since September 06, 2016 until October 20, 2016. Mr. Kinney served as a Chief Scientific Officer and Head of Research & Development at Prothena Corporation plc from December 2012 to October 03,2016. Prior to that, Mr. Kinney was senior vice president of pharmacological sciences (a position he held from 2011 to 2012), and vice president, pharmacology (a position he held from 2009 to 2012) for elan pharmaceuticals, inc; while in those positions, Mr. Kinney also served as head of nonclinical research for janssen alzheimer immunotherapy r&d. from 2001 to 2009, Mr. Kinney was senior director, head of central pharmacology and acting lead for bioanalytics & pathology at the merck research laboratories, where he contributed to the strategic direction and oversight of drug discovery activities and led a number of non-clinical discovery and clinical development programs targeted for the treatment of neurodegenerative and psychiatric conditions. Mr. Kinney has been Director at Prothena Corporation plc since September 2016. Mr. Kinney also held positions at bristol-myers squibb and was an assistant professor at the emory university school of medicine, department of psychiatry and behavioral sciences. Mr. Kinney holds BA from bloomsburg university and his MA and PhD from florida atlantic university.

CEO Compensation

Gene's compensation has increased whilst company is loss making.
Gene's remuneration is higher than average for companies of similar size in Germany.

Management Team Tenure

Average tenure and age of the Prothena management team in years:

2.5

Average Tenure

Average Age

The tenure for the Prothena management team is about average.

TITLE

Head of Communications

Radhika Tripuraneni

TITLE

Chief Development Officer

AGE

38

TENURE

1.3 yrs

Marty Koller

TITLE

Consultant

COMPENSATION

$2M

AGE

67

TENURE

1.2 yrs

Board of Directors Tenure

Average tenure and age of the Prothena board of directors in years:

6.1

Average Tenure

Average Age

The tenure for the Prothena board of directors is about average.

4.3 yrs

Who owns this company?

Recent Insider Trading

No 3 month insider trading information.

Recent Insider Transactions

Announced	Type	Name	Entity	Role		Start	End	Shares	Max Price (€)	Value (€)

Management checks

We assess Prothena's management by checking for:

Is the CEO's compensation unreasonable compared to market cap? (1 check)
Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
Is the average tenure of the management team less than 2 years? (1 check)
Is the average tenure of the board of directors team less than 3 years? (1 check)

Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

0PT News

Simply Wall St News

0PT Company Info

Description

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson’s disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer’s disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.

Details

Name:	Prothena Corporation plc
Ticker:	0PT
Exchange:	DB
Founded:	2012
Market Cap:	$379,280,886
Shares outstanding:	39,863,711
Website:	http://www.prothena.com
Address:	Prothena Corporation plc 77 Sir John Rogerson’s Quay, Block C, Dublin, Co. Dublin, 2, Ireland

Listings

Exchange Symbol	Ticker Symbol	Security	Exchange	Country	Currency	Listed on
NasdaqGS	PRTA	Ordinary Shares	Nasdaq Global Select	US	USD	18. Dec 2012
DB	0PT	Ordinary Shares	Deutsche Boerse AG	DE	EUR	18. Dec 2012
LSE	0Y3M	Ordinary Shares	London Stock Exchange	GB	USD	18. Dec 2012

Number of employees

Current staff

Prothena employees.

Industry

Industry:	Biotechnology
Sector:	Pharmaceuticals & Biotech

Company Analysis and Financial Data Status

Area	Date (UTC time)
Company Analysis updated:	2019/04/19 21:41
End of day share price update:	2019/04/18 00:00
Last estimates confirmation:	2019/03/29
Last earnings filing:	2019/03/15
Last earnings reported:	2018/12/31
Last annual earnings reported:	2018/12/31

All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2019, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2019)